Evidence map›Paper›PMID 42666152›Full record

ArticleFrontiers in oncology2026

Integrating MR dynamic radiomics and clinical parameters for machine learning-based prediction of short-term response to induction chemotherapy in nasopharyngeal carcinoma.

Huizhen Guo, Junyan Zhang, Wei Zhu, Yu Shang, Wenzhi Wang, Hui Xu, Peng An, Yingjian Ye, Jinsong Wang

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huizhen Guo *Department of Music and Dance, Hubei University of Arts and Science, Xiangyang, China.
Junyan Zhang *Department of Music and Dance, Hubei University of Arts and Science, Xiangyang, China.
Wei ZhuDepartment of Radiology, Oncology and Epidemiology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
Yu ShangDepartment of Radiology, Oncology and Epidemiology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
Wenzhi WangDepartment of Radiology, Oncology and Epidemiology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
Hui XuAffiliated Hospital of Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Peng AnDepartment of Radiology, Oncology and Epidemiology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
Yingjian YeDepartment of Radiology, Oncology and Epidemiology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
Jinsong WangDepartment of Music and Dance, Hubei University of Arts and Science, Xiangyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Accurate prediction of short-term response to induction chemotherapy (ICT) in nasopharyngeal carcinoma (NPC) remains a critical unmet clinical need. We aimed to construct a multimodal, interpretable machine learning (ML) framework integrating MR dynamic radiomics (delta radiomics) with clinical parameters to predict ICT response. Methods: A multicenter retrospective study enrolled 216 pathologically confirmed NPC patients from two institutions (Xiangyang No. 1 People's Hospital and Xiangyang Central Hospital, January 2015-September 2024; training cohort n=151, test cohort n=65) and an independent external validation cohort of 87 patients (Affiliated Hospital of Hubei University of Chinese Medicine, February 2017-June 2024). A Delta Radscore was computed from 2,637 candidate features extracted from paired pre- and arterial-phase post-contrast enhanced T1-weighted imaging (CE-T1WI) MRI, quantifying intratumoral microvascular dynamics. After two-stage feature selection (intraclass correlation coefficient [ICC] ≥0.80 stability screening followed by least absolute shrinkage and selection operator (LASSO)-random forest ensemble), eight ML algorithms-XGBoost, CatBoost, support vector machine (SVM), k-nearest neighbors (KNN), and Logistic Regression,etc-were systematically evaluated. SHAP (SHapley Additive exPlanations) analysis provided model interpretability. Independent clinical predictors were identified via uni- and multivariable logistic regression and integrated into a dynamic nomogram. Results: Multivariable logistic regression identified five independent predictors: T stage (OR = 4.29, 95% CI: 1.43-12.82, P = 0.009), lymphocyte count (OR = 2.08, 95% CI: 1.07-4.05, P = 0.031), lactate dehydrogenase (LDH; OR = 1.02, 95% CI: 1.01-1.03, P<0.001), Dynamic Rad_Score (OR = 0.65, 95% CI: 0.57-0.76, P<0.001), and Music Therapy and Psychological Counseling score (MTPC; OR = 0.33, 95% CI: 0.16-0.68, P = 0.026). XGBoost achieved the best performance across all cohorts: training AUC = 0.962 (95% CI: 0.937-0.998), test AUC = 0.861 (95% CI: 0.767-0.954), and external validation AUC = 0.926; significantly outperforming logistic regression (DeLong P<0.05). The nomogram C-index was 0.876, with a calibration Brier score of 0.082. SHAP analysis ranked Dynamic Rad_Score (mean |SHAP|=0.219), MTPC (0.199), LDH (0.177), and T stage (0.156) as the four most impactful predictors. Decision curve analysis confirmed net clinical benefit of XGBoost across threshold probabilities of 20%-85%. Conclusion: An XGBoost-based multimodal interpretable model integrating MR dynamic radiomics with clinical parameters effectively predicts short-term ICT response in NPC, providing a quantifiable, explainable decision-support tool to guide individualized treatment strategies.

Indexed as

delta radiomicsmachine learningMR dynamic radiomicsnasopharyngeal carcinomaXGBoost

Identifiers

PMID42666152
PMCPMC13521794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.